Results 31 to 40 of about 1,869 (168)

Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis: Network Meta-analysis of Efficacy [PDF]

Dermatology and Therapy
Introduction A systematic literature review and network meta-analysis (NMA) were conducted to compare the short-term efficacy of lebrikizumab to other biologic and Janus kinase (JAK) inhibitor monotherapies approved for moderate-to-severe atopic ...
Jonathan I. Silverberg, Thomas Bieber, Amy S. Paller, Lisa Beck, Masahiro Kamata, Luis Puig, Marni Wiseman, Khaled Ezzedine, Alan D. Irvine, Peter Foley, James Del Rosso, Linda Stein Gold, Erin Johansson, Martin Dossenbach, Gaia Gallo, Buelent Akmaz, Marta Casillas, Andrei Karlsson, Tristan Curteis, Raj Chovatiya   +19 more
doaj   +3 more sources

Selective IL-13 inhibitors for the treatment of atopic dermatitis

Drugs in Context, 2021
Background: Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases worldwide. AD pathogenesis is multifactorial, involving environmental and genetic factors.
Francisca Gonçalves, Egídio Freitas, Tiago Torres   +2 more
doaj   +1 more source

Lebrikizumab for atopic dermatitis in the elderly: A case series. [PDF]

JAAD Case Rep
Gruber B.
europepmc   +4 more sources

Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials [PDF]

, 2023
BACKGROUND: Lebrikizumab is a novel, high-affinity monoclonal antibody that selectively binds to interleukin (IL)-13. OBJECTIVES: To evaluate the efficacy and safety of lebrikizumab monotherapy in adolescent and adult patients with moderate-to-severe ...
Morgan-Cox, MaryAnn, David Rosmarin, Blauvelt, Andrew, Morgan-Cox, Mary Ann, Pierce, Evangeline J., Bieber, Thomas, Rosmarin, David, Simpson, Eric L., Elmaraghy, Hany, Natalie, Chitra R, Guttman-Yassky, Emma, Serra-Baldrich, Esther, Garcia Gil, Esther, Thyssen, Jacob Pontoppidan, Simpson, Eric, Silverberg, Jonathan, Jonathan I Silverberg, Zhuqing Liu, Pierce, Evangeline, Eric Simpson, Andrew Blauvelt, Liu, Zhuqing, Chitra R Natalie, Silverberg, Jonathan I, Esther Serra-Baldrich, Thyssen, Jacob P, Natalie, Chitra R., Thomas Bieber, Hany Elmaraghy, Eric Meskimen, Evangeline Pierce, Rosmarin, David M., Xu, Chenjia, Jacob P Thyssen, Meskimen, Eric, Emma Guttman-Yassky, Chenjia Xu, MaryAnn Morgan-Cox, Esther Garcia Gil, García-Gil, Esther, Universitat Autònoma de Barcelona, Serra Baldrich, Esther   +41 more
core   +1 more source

Docking analysis and the possibility of prediction efficacy for an anti-IL-13 biopharmaceutical treatment with tralokinumab and lebrikizumab for bronchial asthma. [PDF]

PLoS ONE, 2017
Interleukin-13 (IL-13) is associated with allergic airway inflammation and airway remodeling. Our group found a variant with a single nucleotide polymorphism in the IL13 gene at position +2044G>A (rs20541) that was expected to result in the non ...
Yutaka Nakamura, Aki Sugano, Mika Ohta, Yutaka Takaoka   +3 more
doaj   +1 more source

Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis

American Journal of Clinical Dermatology, 2023
Atopic dermatitis (AD) is a common, heterogeneous, inflammatory skin disorder characterized by chronic or relapsing eczematous lesions with intense pruritus and discomfort. Affected patients often experience significant impairment in their quality of life, and the treatment of moderate-to-severe AD forms remains challenging.
Diana Bernardo, Thomas Bieber, Tiago Torres   +2 more
openaire   +2 more sources

Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: results from two phase III, randomized, double-blinded, placebo-controlled trials [PDF]

, 2022
Lebrikizumab, a high-affinity IgG-4 monoclonal antibody targeting interleukin (IL)-13, selectively prevents the formation of the IL-13Ra1/IL-4Ra heterodimer receptor signalling complex.
Silverberg, Jonathan I, Guttman-Yassky, Emma, Blauvelt, Andrew, Simpson, Eric, Liu, Zhuqing T, Gontijo Lima, Renata, Chu, Chia-Yu, Thaçi, Diamant, Seneschal, Julien, Pillai, Sreekumar, Stein Gold, Linda F   +10 more
core   +1 more source

Ease of Use of the Lebrikizumab Prefilled Pen for Individuals with Atopic Dermatitis. [PDF]

Patient Prefer Adherence
Atopic dermatitis (AD) is a chronic inflammatory skin disease that can require long-term systemic therapy in individuals with moderate-to-severe disease. Lebrikizumab is a monoclonal antibody that targets interleukin 13, an important cytokine involved in AD pathogenesis.
Soung J, Miller W, Jarell AD, Greenstein D, DeLuca-Carter L, Crane HM, Behling M, Duffy K, Pierce E, Shahriari M.   +9 more
europepmc   +4 more sources

Lebrikizumab for adolescent atopic dermatitis: 24-week real-world outcomes from the Czech BIOREP registry [PDF]

JAAD International
Filip Rob, MD, PhD, Blanka Pinková, MD, PhD, Petra Gkalpakioti, MD, Jiřina Bartoňová, MD, Jiří Horažďovský, MD, PhD, Jan Říčař, MD, PhD, Jana Třešňák Hercogová, MD, PhD, Kristýna Sokolová, MD   +7 more
doaj   +2 more sources

Lebrikizumab-induced psoriasis in a patient with atopic dermatitis. [PDF]

JAAD Case Rep
Cutrona M, Golant AK.
europepmc   +4 more sources